Immunotherapy Emerges in Stage III NSCLC Treatment Landscape – OncLive
OncLive |
Immunotherapy Emerges in Stage III NSCLC Treatment Landscape
OncLive Do you think the success that we have seen with durvalumab is an indicator for upcoming immunotherapy agents in this stage? This is just the beginning. Most of my talk involved discussing questions we still have for stage III disease, as well as … |
